Advanced

Clinical use of C-peptide and β-cell specific autoantibodies during gestational diabetes mellitus

Nilsson, Charlotta LU ; Hillman, Magnus LU ; Ursing, Dag; Strevens, Helena LU and Landin-Olsson, Mona LU (2012) In Practical Diabetes 29(3). p.105-108
Abstract
Gestational diabetes mellitus (GDM) confers a risk for developing type 2 diabetes later in life, but the risk of developing type 1 diabetes is also increased. In this study we have evaluated the clinical use of C-peptide and β-cell specific autoantibodies during pregnancy with GDM as predictors for later development of diabetes.

C-peptide levels were measured 2 hours after glucose intake in pregnancies with GDM during 2006–2008 (n=281). The mother′s age and first weight during pregnancy, birth weight of the newborn and postpartum development of diabetes in the women were noted from their records. Between 1995–2008, 669 women developed GDM and were tested for glutamic acid decarboxylase antibodies (GADA) and tyrosine phosphatase... (More)
Gestational diabetes mellitus (GDM) confers a risk for developing type 2 diabetes later in life, but the risk of developing type 1 diabetes is also increased. In this study we have evaluated the clinical use of C-peptide and β-cell specific autoantibodies during pregnancy with GDM as predictors for later development of diabetes.

C-peptide levels were measured 2 hours after glucose intake in pregnancies with GDM during 2006–2008 (n=281). The mother′s age and first weight during pregnancy, birth weight of the newborn and postpartum development of diabetes in the women were noted from their records. Between 1995–2008, 669 women developed GDM and were tested for glutamic acid decarboxylase antibodies (GADA) and tyrosine phosphatase antibodies (IA-2A); 34 women (5%) were found positive for at least one autoantibody.

The incidence of diabetes was significantly higher (p<0.001) among women with positive autoantibodies (5/12) compared to women without autoantibodies (21/266) during 2006–2008. When comparing stimulated C-peptide during GDM between women who later developed diabetes and those who did not, there was no significant difference. Among the 34 women who were autoantibody positive during their GDM between 1995–2008, 50% (n=17) had developed type 1 diabetes, and an additional five had impaired fasting glucose or impaired glucose tolerance.

In conclusion, stimulated C-peptide values were of no use in women with GDM regarding prediction of future diabetes. Analysis of GAD antibodies during GDM is recommended, due to a high risk of type 1 diabetes after delivery. A structured follow up of all women with GDM ought to be considered. Copyright © 2012 John Wiley & Sons. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Practical Diabetes
volume
29
issue
3
pages
4 pages
publisher
J Wiley
external identifiers
  • scopus:84863714065
ISSN
2047-2900
DOI
10.1002/pdi.1668
language
English
LU publication?
yes
id
2102b163-90a1-4f15-aa28-30671ee5f984
date added to LUP
2017-06-11 17:07:09
date last changed
2017-06-18 05:06:31
@article{2102b163-90a1-4f15-aa28-30671ee5f984,
  abstract     = {Gestational diabetes mellitus (GDM) confers a risk for developing type 2 diabetes later in life, but the risk of developing type 1 diabetes is also increased. In this study we have evaluated the clinical use of C-peptide and β-cell specific autoantibodies during pregnancy with GDM as predictors for later development of diabetes.<br>
<br>
C-peptide levels were measured 2 hours after glucose intake in pregnancies with GDM during 2006–2008 (n=281). The mother′s age and first weight during pregnancy, birth weight of the newborn and postpartum development of diabetes in the women were noted from their records. Between 1995–2008, 669 women developed GDM and were tested for glutamic acid decarboxylase antibodies (GADA) and tyrosine phosphatase antibodies (IA-2A); 34 women (5%) were found positive for at least one autoantibody.<br>
<br>
The incidence of diabetes was significantly higher (p&lt;0.001) among women with positive autoantibodies (5/12) compared to women without autoantibodies (21/266) during 2006–2008. When comparing stimulated C-peptide during GDM between women who later developed diabetes and those who did not, there was no significant difference. Among the 34 women who were autoantibody positive during their GDM between 1995–2008, 50% (n=17) had developed type 1 diabetes, and an additional five had impaired fasting glucose or impaired glucose tolerance.<br>
<br>
In conclusion, stimulated C-peptide values were of no use in women with GDM regarding prediction of future diabetes. Analysis of GAD antibodies during GDM is recommended, due to a high risk of type 1 diabetes after delivery. A structured follow up of all women with GDM ought to be considered. Copyright © 2012 John Wiley &amp; Sons.},
  author       = {Nilsson, Charlotta and Hillman, Magnus and Ursing, Dag and Strevens, Helena and Landin-Olsson, Mona},
  issn         = {2047-2900},
  language     = {eng},
  month        = {04},
  number       = {3},
  pages        = {105--108},
  publisher    = {J Wiley},
  series       = {Practical Diabetes},
  title        = {Clinical use of C-peptide and β-cell specific autoantibodies during gestational diabetes mellitus},
  url          = {http://dx.doi.org/10.1002/pdi.1668},
  volume       = {29},
  year         = {2012},
}